Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.6189.1155
Address
647 Beaufort Street Mt. Lawley, Western Australia (WA) 6050
Description
TrivarX Ltd. engages in clinical research, product development, and early-stage commercialization of mental health technology. Its product is used to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in 1998 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.05
Trade Value (12mth)
AU$5,275.00
1 week
0%
1 month
18.18%
YTD
-27.78%
1 year
-55.17%
All time high
172.93
EPS 3 yr Growth
-78.70%
EBITDA Margin
N/A
Operating Cashflow
-$1m
Free Cash Flow Return
-18.20%
ROIC
-17.70%
Interest Coverage
-165.20
Quick Ratio
0.80
Shares on Issue (Fully Dilluted)
455m
HALO Sector
Technology
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
07 May 25 |
Notification regarding unquoted securities - TRI
×
Notification regarding unquoted securities - TRI |
07 May 25 |
Pilot Agreement - Major League Baseball affiliated Academy
×
Pilot Agreement - Major League Baseball affiliated Academy |
30 April 25 |
March 2025 Quarterly Activities Report and Appendix 4C
×
March 2025 Quarterly Activities Report and Appendix 4C |
28 April 25 |
IRB approval for trial with US Dept of Veterans Affairs
×
IRB approval for trial with US Dept of Veterans Affairs |
03 April 25 |
Letter to Shareholders & Notice of GM & Proxy Form
×
Letter to Shareholders & Notice of GM & Proxy Form |
26 March 25 |
Application for quotation of securities - TRI
×
Application for quotation of securities - TRI |
26 March 25 |
Cleansing Notice
×
Cleansing Notice |
26 March 25 |
Change in substantial holding
×
Change in substantial holding |
25 March 25 |
Proposed issue of securities - TRI
×
Proposed issue of securities - TRI |
24 March 25 |
Application for quotation of securities - TRI
×
Application for quotation of securities - TRI |
24 March 25 |
Cleansing Notice
×
Cleansing Notice |
17 March 25 |
TrivarX Receives Firm Commitments to Raise $2.25 million
×
TrivarX Receives Firm Commitments to Raise $2.25 million |
17 March 25 |
Proposed issue of securities - TRI
×
Proposed issue of securities - TRI |
17 March 25 |
Proposed issue of securities - TRI
×
Proposed issue of securities - TRI |
13 March 25 |
Trial with US Department of Veterans Affairs
×
Trial with US Department of Veterans Affairs |
13 March 25 |
Trading Halt
×
Trading Halt |
28 February 25 |
Appendix 4D & Half-Year Financial Report to 31 December 2024
×
Appendix 4D & Half-Year Financial Report to 31 December 2024 |
31 January 25 |
December 2024 Quarterly Activities Report and Appendix 4C
×
December 2024 Quarterly Activities Report and Appendix 4C |
28 January 25 |
Positive engagement with FDA following meeting for MEB-001
×
Positive engagement with FDA following meeting for MEB-001 |
14 January 25 |
Application for quotation of securities - TRI
×
Application for quotation of securities - TRI |
14 January 25 |
Cleansing Notice
×
Cleansing Notice |
13 January 25 |
Proposed issue of securities - TRI
×
Proposed issue of securities - TRI |
06 December 24 |
TrivarX Receives $1.03m R&D Tax Incentive
×
TrivarX Receives $1.03m R&D Tax Incentive |
05 December 24 |
Notification regarding unquoted securities - TRI
×
Notification regarding unquoted securities - TRI |
05 December 24 |
Cleansing Notice
×
Cleansing Notice |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.